EYP-2301
Serious Retinal Diseases
Pre-clinicalActive - Tox and PK data completed
Key Facts
Indication
Serious Retinal Diseases
Phase
Pre-clinical
Status
Active - Tox and PK data completed
Company
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is focused on redefining the treatment paradigm for serious retinal diseases by creating best-in-class, durable therapies that aim to improve patient outcomes while reducing treatment burden. The company leverages its proprietary Durasert E™ sustained-release technology, which has a proven safety profile across four FDA-approved products. Its lead pipeline asset, DURAVYU™ (vorolanib in Durasert E™), is a novel multi-mechanism tyrosine kinase inhibitor being developed for wet AMD and DME, with pivotal trial readouts expected in 2026. EyePoint is a publicly traded company (NASDAQ: EYPT) led by an experienced team of ophthalmology and biopharmaceutical executives.
View full company profile